-+ 0.00%
-+ 0.00%
-+ 0.00%

SAVARA ANNOUNCES ENCORE PRESENTATIONS OF RESULTS FROM THE PHASE 3 CLINICAL TRIAL OF MOLGRAMOSTIM INHALATION SOLUTION (MOLGRAMOSTIM) IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS (APAP) AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) CONGRESS 2026

Reuters·08/24/2026 20:05:00

Please log in to view news